UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 485

Sortiert nach

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1301-1311

2022

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Link zum Volltext

Verfügbarkeit prüfen

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Clinical lung cancer, 2018-07, Vol.19 (4), p.e533-e536

2018

Link zum Volltext

Verfügbarkeit prüfen

Delivery of nonbiologically-compatible membrane protein constructs to mammalian cells for functional characterization

Biophysical journal, 2023-02, Vol.122 (3), p.344a-344a

2023

Link zum Volltext

Verfügbarkeit prüfen

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

British journal of cancer, 2016-11, Vol.115 (11), p.1313-1320

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of expedited rotator cuff surgery in injured workers: Impact of pathology on readiness for return to work

Journal of orthopaedic surgery (Hong Kong), 2018-09, Vol.26 (3), p.2309499018808362-2309499018808362

2018

Link zum Volltext

Verfügbarkeit prüfen

Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues

Science advances, 2022-12, Vol.8 (50), p.eabq6720-eabq6720

2022

Link zum Volltext

Verfügbarkeit prüfen

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

Frontiers in immunology, 2022-11, Vol.13, p.1026964-1026964

2022

Link zum Volltext

Verfügbarkeit prüfen

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials

Journal of Data Science, 2023-10, Vol.21 (4), p.781-798

2023

Link zum Volltext

Verfügbarkeit prüfen

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Clinical cancer research, 2009-05, Vol.15 (10), p.3600-3609

2009

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

Current therapeutic research, 2021-01, Vol.95, p.100640-100640, Article 100640

2021

Link zum Volltext

Verfügbarkeit prüfen

The validation of published utility mapping algorithms: An example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer

Health economics review, 2020-04, Vol.10 (10), p.1-10, Article 10

2020

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Link zum Volltext

Verfügbarkeit prüfen

Disentangling human TRPV1 polymodal activation and mechanisms

Biophysical journal, 2024-02, Vol.123 (3), p.38a-38a

2024

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of a Multidisciplinary Rehabilitation Program Following Shoulder Injury

The Open Journal of Occupational Therapy, 2017-07, Vol.5 (3), p.4

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8610-TPS8610

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial

Journal of clinical oncology, 2018-06, Vol.36 (18), p.1853-1860

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Gynecologic oncology, 2016-02, Vol.140 (2), p.199-203

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.489-489

2021

Link zum Volltext

Verfügbarkeit prüfen

A national census of forensic in‐patients with intellectual disability and five‐year follow‐up

Journal of policy and practice in intellectual disabilities, 2022-09, Vol.19 (3), p.321-332

2022

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Cancer, 2019-03, Vol.125 (6), p.892-901

2019

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.657-663

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 485

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(434)
Mit Volltextzugriff
(423)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Delivery of nonbiologically-compatible membrane protein constructs to mammalian cells for functional characterization

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Outcomes of expedited rotator cuff surgery in injured workers: Impact of pathology on readiness for return to work

Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

The validation of published utility mapping algorithms: An example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Disentangling human TRPV1 polymodal activation and mechanisms

Effectiveness of a Multidisciplinary Rehabilitation Program Following Shoulder Injury

Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9)

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab

A national census of forensic in‐patients with intellectual disability and five‐year follow‐up

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

Suchergebnisse filtern